CLR 131 clinical trials
CLR 131 is named as an intervention in 4 current clinical trials in our USA, Australia, Canada, UK, France, Spain, Czechia, Turkey, Brazil and Israel registers. 1 is recruiting patients now. The most common phase is Phase 1. The lead sponsor is Cellectar Biosciences, Inc. The most-studied condition is Waldenstrom Macroglobulinemia.
How CLR 131 works
All drug targets →- B-cell chronic lymphocytic leukemiaPhase 2
- Waldenstrom macroglobulinemiaPhase 2
- Diffuse large B-cell lymphomaPhase 2
- Lymphoplasmacytic lymphomaPhase 2
- Mantle cell lymphomaPhase 2
- Marginal zone lymphomaPhase 2
- ParagangliomaPhase 2
- Plasma cell myelomaPhase 2
- Primary central nervous system lymphomaPhase 2
- Non-small cell lung carcinomaPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297495, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for CLR 131
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of CLR 131
4 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
NCT07311993 · Breast Cancer
|
Phase 1 | Recruiting | Cellectar Biosciences, Inc | USA |
|
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
NCT02952508 · Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia
|
Phase 2 | Active, closed | Cellectar Biosciences, Inc | UK, USA, France, Spain, Czechia, Turkey, Brazil, Australia, Israel |
|
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
NCT03478462 · Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor
|
Phase 1 | Active, closed | Cellectar Biosciences, Inc | USA, Canada, Australia |
|
Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG
NCT05610891 · ClinicalTrials.gov ↗ · High-Grade Glioma
|
Phase 1 | Active, closed | Cellectar Biosciences, Inc | USA, Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with CLR 131
10 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Cellectar Biosciences, Inc | 4 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about CLR 131 trials
How many clinical trials are testing CLR 131?
4 current trials in our USA, Australia, Canada, UK, France, Spain, Czechia, Turkey, Brazil and Israel registers name CLR 131 (also registered as Iopofosine I 131 single) as a drug or biological intervention, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are CLR 131 trials recruiting patients?
Yes. 1 of the 4 trials is recruiting: 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors CLR 131 clinical trials?
The lead sponsor is Cellectar Biosciences, Inc. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how CLR 131 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how CLR 131 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CLR 131 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.